Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804590 | 0.91 | MTNR1A (0.59) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3363396 | 0.77 | MTNR1A (0.62) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8915482 | 0.77 | SMN1; SMN2 (0.62) | RAB9ASMN1; SMN2HPGDL3MBTL1MAPK1 | |
| Pyridine SCHEMBL6763848 | 0.76 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1MAPK1 | |
| SCHEMBL8768565 | 0.75 | TAAR1 (0.56) | RAB9ASMN1; SMN2NPC1DRD2DRD4 | |
| SCHEMBL1053081 | 0.74 | MTNR1A (0.69) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL10310294 | 0.74 | MTNR1A (0.59) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6766219 | 0.74 | POLB (0.72) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8914946 | 0.73 | BCL6 (0.66) | RAB9ASMN1; SMN2NPC1HPGDL3MBTL1 | |
| SCHEMBL27771374 | 0.73 | ALDH1A1 (0.42) | MTNR1AMTNR1BRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022753-A1 | METHOD FOR MODIFYING THIOL GROUP | TAIPEI MEDICAL UNIVERSITY (TW) | 2010-01-28 | — | — | US | disclosed |
| US-6727265-B2 | REVERSE TRANSCRIPTASE INHIBITORS FOR DRUG RESISTANT PATIENTS | PARKER HUGHES INSTITUTE | 2004-04-27 | — | — | US | disclosed |
| US-6727265-B2 | REVERSE TRANSCRIPTASE INHIBITORS FOR DRUG RESISTANT PATIENTS | PARKER HUGHES INSTITUTE | 2004-04-27 | — | — | US | disclosed |
| US-6727265-B2 | REVERSE TRANSCRIPTASE INHIBITORS FOR DRUG RESISTANT PATIENTS | PARKER HUGHES INSTITUTE | 2004-04-27 | — | — | US | disclosed |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | PARKER HUGHES INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | PARKER HUGHES INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | PARKER HUGHES INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002032873-A1 | PHENOXYETHYL-THIOUREA-PYRIDINE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV-INFECTIONS | PARKER HUGHES INSTITUTE (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032873-A1 | PHENOXYETHYL-THIOUREA-PYRIDINE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV-INFECTIONS | PARKER HUGHES INSTITUTE (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | TPMT, TERT, TET1 | MTNR1A 3015/4885MTNR1B 3045/4885RAB9A 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.